Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingBlue Cross Blue Shield - Kansas FDG‑PET Coverage U…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - KansasPolicy N/A

    FDG-PET/PET-CT for Gastrointestinal and Pancreatic Oncology

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines when fluorine-18 FDG PET or PET/CT is considered medically necessary, investigational, or not medically necessary for diagnosis, staging, restaging, and surveillance of colorectal, esophageal, gastric, and pancreatic cancers for Blue Cross and Blue Shield of Kansas members.

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyFDG-PET/PET-CT for Gastrointestinal and Pancreatic Oncology
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 13, 2026
    Last ReviewJan 13, 2026
    Next Review DateJan 13, 2026
    Key ActionObtain prior authorization when PET/CT is requested outside guideline-supported indications and document prior high-quality CT when PET/CT is used as an adjunct.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4cancer types addressed
    PET/PET-CTModalities covered
    Sep 17, 2025Evidence update through
    95%Recurrent CRC sensitivity
    99%Primary CRC sensitivity

    Coverage Criteria — FDG-PET / PET-CT for GI and Pancreatic Cancers

    Initial/Restaging and Rising CEA

    Colorectal cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met

    Colorectal PET necessity: a. Staging or restaging to detect and assess resectability of hepatic or extrahepatic metastases of colorectal cancer; AND b. To evaluate a rising and persistently elevated carcinoembryonic antigen (CEA) level when standard imaging, including CT scan, is negative.

    From policy section A.1

    Colorectal - Experimental/Investigational Uses

    Colorectal cancer — Experimental / investigational (Not covered)

    Colorectal experimental uses: a. A technique to assess the presence of scarring versus local bowel recurrence in individuals with previously resected colorectal cancer; b. A technique contributing to radiotherapy treatment planning.

    From policy section A.2

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyFDG-PET/PET-CT for Gastrointestinal and Pancreatic Oncology
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 13, 2026
    Last ReviewJan 13, 2026
    Next Review DateJan 13, 2026
    Key ActionObtain prior authorization when PET/CT is requested outside guideline-supported indications and document prior high-quality CT when PET/CT is used as an adjunct.
    SourceLink
    On This Page
    Coverage Criteria — FDG-PET / PET-CT for GI and Pancreatic CancersCovered Indications and Acceptable UsesProvider Actions, Prior Authorization, and DocumentationCoding and Billing GuidancePrior Authorization Rules and ExceptionsContrast and Anatomic Imaging RulesNot Medically Necessary / Not Covered UsesDefinitions and Test ConceptsBackground and Evidence OverviewReferences, Supplemental Tables, and Evidence AppendixRevision History and Document Dates

    Esophageal - Staging and Response Assessment

    Esophageal cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met

    Esophageal PET necessity: a. Staging of esophageal cancer; AND b. Determining response to preoperative induction therapy.

    From policy section B.1

    Esophageal - Experimental/Investigational Uses

    Esophageal cancer — Experimental / investigational (Not covered)

    Esophageal experimental uses: Detection of primary esophageal cancer and other aspects of evaluation not listed as medically necessary.

    From policy section B.2

    Gastric - Initial Staging and Recurrent Disease

    Gastric cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met

    Gastric PET necessity: a. Initial diagnosis and staging of gastric cancer; AND b. Evaluation for recurrent gastric cancer after surgical resection when other imaging modalities are inconclusive.

    From policy section C.1

    Pancreatic - Initial Diagnosis/Staging when other tests inconclusive

    Pancreatic cancer — FDG-PET or FDG-PET/CT may be considered medically necessary when ALL of the following are met

    Pancreatic PET necessity: Initial diagnosis and staging of pancreatic cancer when other imaging and biopsy are inconclusive.

    From policy section D.1

    Pancreatic - Experimental/Investigational Uses

    Pancreatic cancer — Experimental / investigational (Not covered)

    Pancreatic experimental uses: Other aspects of pancreatic cancer evaluation not specified as medically necessary.

    From policy section D.2

    Colorectal cancer (CRC) coverage rationale

    Findings from systematic reviews, meta-analyses, and a randomized trial inform coverage stance for colorectal cancer:

    CRC - diagnostic accuracy: FDG-PET/CT demonstrates high sensitivity but variable and sometimes low specificity for detection of primary tumor, nodal disease, metastases, and recurrence; pooled estimates include primary tumor sensitivity ~99%/specificity ~67% and recurrent CRC sensitivity ~95%/specificity ~93%.

    See pooled estimates in chunks 25, 28, 30.

    CRC - clinical utility: Evidence did not show PET or PET/CT provides benefit over contrast-enhanced CT for diagnosis, staging, restaging, or surveillance; a randomized trial (N=239) found no difference in outcomes when adding 6-monthly FDG-PET/CT to usual surveillance.

    See chunks 31 and 35.

    Guideline-based use constraints and recommended uses

    Guideline-based constraints and recommended uses:

    When PET/CT may be appropriate: Use PET/CT to evaluate equivocal findings on contrast-enhanced CT or MRI, in patients with contraindications to IV contrast, for selected individuals with potentially resectable M1 disease, for consideration in image-guided liver-directed therapies, and for rising carcinoembryonic antigen where other imaging is non-diagnostic.

    Based on ACR and NCCN guidance (chunks 32-34).

    When PET/CT not routinely indicated: PET/CT is not routinely indicated for initial workup of nonmetastatic disease, routine staging, baseline imaging, routine follow-up, restaging, or assessing response to chemotherapy in colorectal and rectal cancer patients.

    Based on NCCN and ACR statements (chunks 32-34).

    Esophageal cancer

    Esophageal cancer evidence summary:

    Esophageal cancer - primary detection: PET is generally not considered useful for detecting primary esophageal tumors and evidence is lacking that it can reliably differentiate malignant from benign esophageal conditions.

    Chunk 36.

    Esophageal cancer - metastases and response: Pooled proportion of true distant metastases detected after neoadjuvant therapy is about 8% with FDG-PET/CT and pooled false-positive distant findings about 5%; PET during or after neoadjuvant chemoradiotherapy shows moderate-high sensitivity (67%–85%) and variable specificity (59%–69%) for predicting tumor response.

    Chunk 37.

    Esophageal Cancer - Supported Uses

    Covered when ALL of the following are met for esophageal cancer:

    Esophageal - Indications: FDG-PET/CT is supported for staging, restaging, and assessment of response to neoadjuvant therapy or detection of recurrence; PET alone is generally not considered for detecting primary esophageal tumors and surveillance use is not supported.

    Guidelines (ACR, NCCN) consider PET/CT appropriate for pretreatment staging and post-treatment imaging; PET alone is less favored for initial tumor detection.

    Gastric Cancer - Supported Uses

    Covered when ALL of the following are met for gastric cancer:

    Gastric - Indications: FDG-PET/CT is supported for initial diagnosis and staging and for detection of recurrent gastric cancer when other imaging is inconclusive; PET/CT may be used to evaluate response in selected cases. Routine surveillance use is not supported.

    NCCN allows FDG-PET/CT as part of initial workup for locally advanced or metastatic disease and when clinically indicated; CT preferred for routine surveillance.

    Pancreatic Cancer - Conditional Uses

    Covered when ALL of the following are met for pancreatic cancer:

    Pancreatic - Indications: FDG-PET/CT is supported as a supplemental imaging evaluation when high-quality contrast-enhanced CT or biopsy is inconclusive, or to detect additional distant metastases when clinically indicated; PET/CT is not a substitute for diagnostic CT and is not routinely used for initial diagnosis, staging, restaging, or surveillance.

    NCCN and ACR: consider PET/CT after formal pancreatic CT protocol in high-risk patients; evidence shows PET/CT can improve detection of distant metastases compared with CT alone (Ghaneh et al).

    Table 3: National FDG PET Coverage by tumor type and treatment strategy

    National FDG PET Coverage (Table 3) — coverage stance by tumor type and treatment strategy

    Colorectal coverage: Colorectal: Initial treatment strategy = Cover; Subsequent treatment strategy = Cover

    Table 3 summary (chunk 57)

    Esophagus coverage: Esophagus: Initial treatment strategy = Cover; Subsequent treatment strategy = Cover

    Table 3 summary (chunk 57)

    Pancreas coverage: Pancreas: Initial treatment strategy = Cover; Subsequent treatment strategy = Cover

    Table 3 summary (chunk 58)

    Prostate coverage note: Prostate: Initial treatment strategy = Non-cover; Subsequent treatment strategy = Cover

    Table 3 summary (chunk 58)

    Other tumor coverage: All other solid tumors and listed cancers: Initial = Cover (with exceptions for some sites); Subsequent = Cover

    Table 3 summary (chunks 57-59)

    Colorectal cancer: FDG‑PET or FDG‑PET/CT may be considered medically necessary when both of the following criteria are met: (1) staging or restaging to detect and assess resectability of hepatic or extrahepatic metastases; AND (2) evaluation of a rising and persistently elevated carcinoembryonic antigen (CEA) level when standard imaging (including CT) is negative. This policy position reflects pooled diagnostic evidence showing high sensitivity but variable and at times low specificity for primary, nodal, metastatic, and recurrent disease, and randomized trial data that adding scheduled PET/CT to routine surveillance did not improve outcomes (RCT N=239). Clinicians should follow guideline recommendations (eg, NCCN) that PET/CT not supplant contrast‑enhanced diagnostic CT or MRI and to reserve PET/CT for equivocal anatomic findings, contraindication to IV contrast, selected patients considered for liver‑directed therapies, or when rising CEA is unexplained by other imaging.

    Colorectal — Experimental/Investigational (Not covered): FDG‑PET or FDG‑PET/CT is considered experimental/investigational and not covered for (a) assessing scarring versus local bowel recurrence after prior resection and (b) contribution to radiotherapy treatment planning. The overall evidence does not demonstrate a benefit of routine PET or PET/CT over contrast‑enhanced CT for diagnosis, staging, restaging, or surveillance of colorectal cancer, and major guidelines (NCCN) strongly discourage routine PET/CT for staging, baseline imaging, or routine follow‑up except in the limited, guideline‑specified circumstances noted above.

    Esophageal cancer — Supported uses: FDG‑PET or FDG‑PET/CT may be considered medically necessary for staging of esophageal cancer and for determining response to preoperative induction (neoadjuvant) therapy. Evidence from meta‑analyses demonstrates high sensitivity and supports use of PET/CT for diagnosis, staging, restaging, and response assessment in selected patients; relevant guidelines (ACR, NCCN) endorse PET/CT (not PET alone) for pretreatment staging and for assessment of treatment response in appropriate clinical contexts.

    Esophageal — Experimental/Investigational (Not covered): FDG‑PET or FDG‑PET/CT is considered experimental/investigational and not covered for indications outside those listed as medically necessary, including the use of PET (alone) to detect primary esophageal cancer. PET alone is generally not considered useful to detect primary esophageal tumors or to distinguish malignant from benign esophageal conditions.

    Gastric cancer — Supported uses: FDG‑PET or FDG‑PET/CT may be considered medically necessary for initial diagnosis and staging of gastric cancer and for evaluation of suspected recurrent gastric cancer after resection when other imaging modalities are inconclusive. Meta‑analyses report pooled sensitivity estimates generally in the high 70s to mid‑80s and specificity in the high 70s to high 80s; guidelines (eg, NCCN) permit FDG‑PET/CT as part of the initial workup for locally advanced or metastatic gastric disease or when clinically indicated. Routine surveillance with PET or PET/CT is not supported by the evidence.

    Pancreatic cancer — Conditional uses: FDG‑PET or FDG‑PET/CT may be considered medically necessary for initial diagnosis and staging when high‑quality contrast‑enhanced CT and biopsy are inconclusive or when PET/CT is expected to detect additional distant metastases that would alter management. Systematic reviews and a large observational study show that PET/CT can improve detection of distant metastases compared with CT alone in selected patients; however, PET/CT is not supported as a routine substitute for diagnostic CT, nor is it supported for routine staging, restaging, or surveillance.

    Table 3 — National FDG PET Coverage by tumor type and treatment strategy: The national FDG PET coverage summary indicates that FDG‑PET is generally listed as Cover for both initial and subsequent treatment strategies for colorectal, esophageal, pancreatic, and most other solid tumors, with specific exceptions (for example, prostate cancer initial treatment strategy is listed as Non‑cover). These table entries reflect a broad national coverage framework but do not replace the clinical‑indication‑specific policy criteria in this document; coverage remains contingent on meeting the policy's stated medical‑necessity criteria and the member's contract.

    Not medically necessary / clinical impact requirement: When the PET or PET/CT result will not influence treatment decisions, the service is considered not medically necessary and may be denied. This policy applies to both PET alone and PET with CT; codes listed in the coding section are medically necessary only if the procedure is performed in accordance with the policy criteria. For colorectal cancer specifically, evidence and guideline summaries do not support routine use of FDG‑PET or PET/CT for diagnosis, staging, restaging, or surveillance.

    Routine use not supported for colorectal disease: Use of FDG‑PET and FDG‑PET/CT for routine diagnosis, initial staging, restaging, or surveillance of colorectal cancer is not supported by the evidence. A randomized trial that added 6‑monthly FDG‑PET/CT to usual surveillance in patients in remission found no statistically significant improvement in outcomes compared with usual surveillance alone. Major guidelines (NCCN) strongly discourage routine PET/CT for initial staging or routine follow‑up and recommend PET/CT be reserved for the limited situations described above.

    Covered Indications and Acceptable Uses

    Colorectal cancer

    Colorectal cancer — single top-level coverage node

    Colorectal top-level: Staging/restaging to detect and assess resectability of hepatic or extrahepatic metastases; AND evaluation of rising and persistently elevated CEA when standard imaging including CT is negative.

    Coverage criterion (Chunk 9)

    Esophageal cancer

    Esophageal cancer — single top-level coverage node

    Esophageal top-level: Staging of esophageal cancer; AND determining response to preoperative induction therapy.

    Coverage criterion (Chunk 10)

    Gastric cancer

    Gastric cancer — single top-level coverage node

    Gastric top-level: Initial diagnosis and staging of gastric cancer; AND evaluation for recurrent gastric cancer after surgical resection when other imaging modalities are inconclusive.

    Coverage criterion (Chunk 11)

    Pancreatic cancer

    Pancreatic cancer — single top-level coverage node

    Pancreatic top-level: Initial diagnosis and staging of pancreatic cancer when other imaging and biopsy are inconclusive.

    Coverage criterion (Chunk 12)

    Acceptable selective uses of PET/CT in GI cancers (not routine)

    Acceptable selective uses of PET/CT in GI cancers (not routine) — top-level nodes:

    Equivocal anatomic imaging: Equivocal finding on contrast-enhanced CT or MRI that requires metabolic imaging clarification.

    NCCN/ACR guidance (Chunks 33-34).

    Selected for liver-directed therapy: Selected patients with suspected surgically curable M1 disease to assess for extrahepatic disease or operability prior to liver-directed therapy.

    NCCN/ACR guidance and clinical context (Chunks 26, 33-34).

    Rising CEA with non-diagnostic imaging: Rising carcinoembryonic antigen with non-diagnostic anatomic imaging where PET/CT may localize recurrence.

    Based on evidence and guidelines (Chunks 26, 30, 33).

    Staging and response assessment

    Staging and response assessment — coverage node

    Staging/Response: Skull base to mid-thigh PET/CT is usually appropriate for pretreatment clinical staging of esophageal cancer and can be part of initial workup to assess response to chemoradiation; PET/CT (not PET alone) may be used for staging and response assessment in selected GI cancers per ACR/NCCN.

    ACR/NCCN recommendations (Chunks 39, 40, 51).

    Pancreatic staging when CT inconclusive

    Pancreatic staging when CT inconclusive — coverage node

    Pancreatic supplemental PET/CT: Consider PET/CT as supplemental imaging to detect additional distant metastases or when high-quality contrast-enhanced pancreatic CT is inconclusive; PET/CT is not a substitute for diagnostic CT.

    ACR and NCCN guidance (Chunks 50-52).

    FDG-PET/PET-CT oncologic indications summarized

    FDG-PET/PET-CT oncologic indications summarized in national coverage table:

    Table coverage — summary: Table 3 lists multiple tumor types with initial and subsequent treatment strategies generally covered (examples include colorectal, esophagus, pancreas listed as Cover for initial and subsequent strategies).

    Table 3 summary (Chunks 56-59).

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization applies to PET and PET/CT; evaluate by indication and timing

    Prior authorization processes should treat PET and PET/CT equivalently: PET scans and PET plus CT scans are evaluated for medical necessity based on the specific clinical indication and timing (for example, surveillance is defined as imaging ≥6 months after treatment, or ≥12 months for lymphoma).

    • Policy statements apply to both PET alone and PET+CT.
    • Medical necessity determinations depend on indication and timing (surveillance threshold: ≥6 months; ≥12 months for lymphoma).
    Prior Authorization

    Prior authorization recommended for PET/CT requests outside guideline-supported indications

    Obtain prior authorization when requesting PET/CT for staging, restaging, or surveillance outside guideline-supported indications (eg, routine baseline imaging or surveillance). Requests for PET/CT to evaluate equivocal anatomic findings, in patients with contraindication to IV contrast, or for selected preoperative/ liver-directed therapy cases are the guideline-supported exceptions.

    • NCCN: routine PET/CT for staging, baseline imaging, or routine follow-up is strongly discouraged.
    • Use PET/CT only for equivocal contrast-enhanced CT/MR findings or when IV contrast is contraindicated, or in selected cases (eg, potentially resectable M1 disease or image-guided liver-directed therapy).
    Prior Authorization

    Require prior pancreatic CT protocol before PET/CT for staging

    For pancreatic cancer staging, prior high-quality contrast-enhanced CT performed with a formal pancreatic CT protocol is expected before considering PET/CT; PET/CT may be considered only after that pancreatic CT protocol in high-risk patients to detect extrapancreatic metastasis.

    • NCCN: PET/CT may be considered after formal pancreatic CT protocol in high-risk patients and is not a substitute for high-quality contrast-enhanced CT.
    • Documentation of prior pancreatic CT protocol should be available when seeking PET/CT for pancreatic staging.
    Billing Rule

    Codes provided for informational/prior-authorization use; coverage depends on Policy

    The policy lists procedure and radiopharmaceutical codes for informational and prior-authorization relevance; inclusion of codes does not by itself imply coverage and codes are medically necessary only if procedure is performed according to the Policy section.

    • Coding list includes CPT/HCPCS codes for PET imaging (eg, 78812, 78815, 78816) and radiopharmaceuticals (eg, A9552, A9597, A9598).
    • Refer to member contract and Policy section to determine coverage and reimbursement.
    Note

    (No additional provider action in source)

    The source does not include additional provider-action requirements under this placeholder.

    Step Therapy

    Require prior contrast-enhanced CT/MRI before PET/CT unless contraindicated

    Require prior diagnostic anatomic imaging (contrast-enhanced CT or MRI) be available and reviewed before approving PET/CT except when IV contrast is contraindicated or when PET/CT is otherwise specifically indicated.

    • PET/CT should not routinely replace contrast-enhanced diagnostic CT or MRI when those studies are available and diagnostic.
    • Exceptions include equivocal findings on anatomic imaging or strong contraindication to IV contrast.
    Step Therapy

    Perform pancreatic CT protocol first; PET/CT only afterward for extrapancreatic metastasis

    When evaluating for extrapancreatic metastasis in suspected pancreatic cancer, require completion of a formal contrast-enhanced pancreatic CT protocol first; consider PET/CT only if that CT protocol is complete and CT is inconclusive or additional metastatic evaluation is needed.

    • PET/CT is not a substitute for high-quality contrast-enhanced CT.
    • NCCN recommends PET/CT consideration after formal pancreatic CT protocol in high-risk patients.
    Note

    (No additional provider action in source)

    The source does not identify additional provider-action text for this placeholder beyond existing requirements.

    Documentation Required

    Confirm surveillance timing for prior authorization (≥6 months; ≥12 months for lymphoma)

    For surveillance requests, verify timing relative to treatment: imaging is considered surveillance when completed ≥6 months after completion of treatment (and ≥12 months for lymphoma); prior authorization should reflect these timing thresholds.

    • Surveillance definition: ≥6 months post-treatment (≥12 months for lymphoma).
    • Use timing to determine whether request is for surveillance versus restaging.
    Documentation Required

    Document limited PET/CT use: equivocal CT/MRI, contrast contraindication, or other exceptions

    Include documentation that PET/CT is limited to situations of equivocal anatomic imaging, IV contrast contraindication, selection for liver-directed therapies, or other guideline-supported exceptions when seeking prior authorization.

    • Documentation should state why contrast-enhanced CT/MRI is non-diagnostic or why IV contrast cannot be used.
    • Indicate intended clinical management changes (eg, selection for liver-directed therapy) to support necessity.
    Documentation Required

    Document prior CT and clinical rationale when PET/CT is adjunct or CT is inconclusive

    When PET/CT is requested as an adjunct after CT or because CT is inconclusive, submit prior CT images and a clinical rationale explaining how PET/CT results are expected to change management.

    • Provide prior high-quality CT imaging used in the diagnostic workup (eg, multidetector CT).
    • Explain expected impact of PET/CT on staging or treatment decisions (management-impact rationale).
    Billing Rule

    Coding note: codes medically necessary only if procedure meets Policy criteria

    Codes listed in the Coding section are medically necessary only if the procedure is performed in accordance with the Policy section; inclusion of codes does not guarantee member coverage or provider reimbursement.

    • Refer to the Policy section and member contract benefits at time of service to determine coverage.
    • Presence of a code in the list is informational and not a standalone coverage determination.
    Denial Risk

    Deny if PET results will not influence treatment decisions

    Requests may be denied if PET/PET-CT results are unlikely to influence treatment decisions; the policy states services are not medically necessary when results will not affect management.

    • Prior authorization should include a statement of how PET results will influence care.
    • If no plausible management change is documented, coverage may be denied as not medically necessary.
    Denial Risk

    NCCN discouragement of routine PET/CT in colon cancer may trigger denial

    Routine or non-guideline PET/CT use in colon cancer may be denied consistent with NCCN guidance, which strongly discourages routine PET/CT for staging, baseline imaging, or routine follow-up.

    • NCCN: PET/CT not routinely indicated for initial workup of nonmetastatic disease; discouraged for routine follow-up.
    • Prior authorization should reference NCCN guidance when evaluating colon cancer PET/CT requests.
    Denial Risk

    Surveillance PET/CT for esophageal, gastric, or pancreatic cancer is unsupported and may be denied

    Requests for PET or PET/CT for routine surveillance in esophageal, gastric, or pancreatic cancer are unsupported by the evidence and may be denied.

    • Evidence sections state that surveillance use is not supported for esophageal, gastric, or pancreatic cancers.
    • Prior authorization should flag surveillance requests for these tumor types for potential denial.
    Denial Risk

    Coverage contingent on meeting Policy criteria despite listed codes

    Inclusion or exclusion of procedure or diagnosis codes in the Coding section does not by itself determine member coverage or provider reimbursement; coverage is contingent on the Policy criteria and the member's contract.

    • Verify member contract benefits at time of service.
    • Confirm the procedure meets Policy clinical criteria to establish medical necessity.

    Coding and Billing Guidance

    Covered/Discussed Modalitiesmixed
    18F-FDG-PETFluorine-18 fluorodeoxyglucose positron emission tomography (as described in policy)
    18F-FDG-PET/CTFluorine-18 fluorodeoxyglucose PET with computed tomography fusion
    Policy Notesmixed
    POLICYAll policy statements apply to both PET scans and PET plus CT scans (PET with or without PET/CT fusion).
    Relevant CPT/HCPCS codes (informational)mixed
    78608Brain imaging, positron emission tomography (PET); metabolic evaluation
    78609Brain imaging, positron emission tomography (PET); perfusion evaluation
    78811Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck)
    78812Positron emission tomography (PET) imaging; skull base to mid-thigh
    78813Positron emission tomography (PET) imaging; whole body
    78814Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; limited area (e.g. chest, head/neck)
    78815Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; skull base to mid-thigh
    78816Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; whole body
    A9552Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 millicuries
    A9597Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified
    1–10 of 12
    1/2
    Surveillance timing summary (authorization timeline)
    Surveillance definitionImaging completed ≥6 months after completion of treatment (≥12 months for lymphoma).
    Authorization timing implicationClassify requests as surveillance only if imaging is ≥6 months post-treatment (use ≥12 months threshold for lymphoma).
    Prior authorization notePrior authorization decisions should evaluate timing relative to treatment to determine surveillance status.
    Note

    Informational list of PET procedure and radiopharmaceutical codes

    Procedure and radiopharmaceutical codes are listed for informational and prior-authorization relevance; see Coding section for the CPT/HCPCS codes included in the policy.

    • Included codes cover PET imaging CPTs (78811–78816), brain PET codes (78608–78609), radiopharmaceuticals (A9552, A9597, A9598), and G0235.
    • Use the code list to prepare prior-authorization submissions but confirm medical necessity per Policy.

    Prior Authorization Rules and Exceptions

    Prior Authorization

    Evaluate PET/PET-CT prior authorization by indication and surveillance timing

    Prior authorization determinations for PET and PET/CT are based on the indication and timing; surveillance is defined as imaging performed ≥6 months after treatment (≥12 months for lymphoma).

    • Evaluate requests against covered indications and surveillance timing thresholds.
    • Confirm whether the request is for surveillance versus restaging to apply correct criteria.
    Prior Authorization

    Require prior authorization for PET/CT when used outside guideline-supported indications

    Prior authorization should be obtained for PET/CT requests outside guideline-supported indications; guideline-supported exceptions include equivocal anatomic imaging, IV contrast contraindication, or selection for liver-directed or other specialized therapies.

    • PET/CT should only replace contrast-enhanced CT/MRI when those studies are equivocal or cannot be performed because of contrast contraindication.
    • Requests for PET/CT for routine staging or surveillance should be subjected to prior-authorization review.
    Prior Authorization

    Require formal pancreatic CT protocol documentation before PET/CT approval

    For pancreatic cancer, prior authorization should require documentation that a formal pancreatic CT protocol was completed and that CT was inconclusive before approving PET/CT.

    • NCCN: consider PET/CT after formal pancreatic CT protocol in high-risk patients.
    • Note that PET/CT is not a substitute for high-quality contrast-enhanced CT.
    Note

    Administrative note: prior authorization depends on policy implementation and coding

    Prior authorization and implementation details may vary because the policy was split into a separate document; follow payer-specific prior authorization processes and reference the policy language and coding when applicable.

    • Administrative note: Oncologic Applications Gastrointestinal and Pancreatic policy was separated from the broader PET policy.
    • Prior authorization requirements depend on payer policy implementation and member benefits.

    Contrast and Anatomic Imaging Rules

    Note

    Policy applies to PET alone and PET plus CT

    Policy statements explicitly apply to PET scans and PET plus CT scans (PET with or without PET/CT fusion); treat both modalities under the same coverage rules.

    • All policy statements apply to both PET and PET+CT.
    • When submitting prior authorization, indicate whether PET alone or PET/CT is requested but expect equivalent evaluation.
    Billing Rule

    Do not substitute PET/CT for diagnostic contrast-enhanced CT/MRI when those studies are available

    When a diagnostic contrast-enhanced CT or MRI is available and is diagnostic, PET/CT should not routinely replace that anatomic imaging; PET/CT should be reserved for equivocal anatomic findings or when IV contrast cannot be used.

    • PET/CT does not supplant contrast-enhanced diagnostic CT/MR and should be used to evaluate equivocal findings or in contrast-contraindicated patients.
    • Prior authorization should document why contrast-enhanced anatomic imaging is inadequate if PET/CT is requested instead.
    Billing Rule

    PET/CT is not a substitute for high-quality pancreatic contrast CT; use only after pancreatic CT protocol

    For pancreatic imaging, PET/CT is not a substitute for high-quality, contrast-enhanced CT; PET/CT may be considered only after completion of a formal pancreatic CT protocol or when CT contrast cannot be used (eg, renal insufficiency or contrast allergy).

    • NCCN: PET/CT may be considered after formal pancreatic CT protocol in high-risk patients to detect extrapancreatic metastasis.
    • Document contraindications to CT contrast if relying on PET/CT due to inability to perform contrast-enhanced CT.

    Not Medically Necessary / Not Covered Uses

    Examples of not-covered scenarios provided in the policy include: using PET to detect a primary esophageal cancer (PET alone is not appropriate for primary detection), employing PET to distinguish scarring versus local recurrence in colorectal cancer after resection, and other pancreatic applications that are not specified as medically necessary. These examples are identified as experimental/investigational and therefore not covered.

    Requests for routine PET/CT for staging, baseline imaging, routine surveillance, or to assess chemotherapy response in colorectal or rectal cancer are not supported by current guidelines (NCCN/ACR) and the evidence. The policy and guideline statements strongly discourage routine PET/CT in these scenarios except in selected circumstances (eg, equivocal anatomic imaging or suspected resectable M1 disease).

    The policy emphasizes that PET alone is inadequate for detecting primary esophageal tumors and that PET or PET/CT is not supported for routine surveillance across esophageal, gastric, and pancreatic cancers. These conclusions are drawn from systematic reviews and guideline recommendations summarized in the document.

    Additional not-covered language in the policy reiterates that specific applications outside the listed medically necessary indications—such as other diagnostic uses not enumerated for colorectal, esophageal, gastric, or pancreatic cancers—are considered experimental or investigational and not covered.

    Definitions and Test Concepts

    Diagnosis — definition
    DefinitionDiagnosis: use of PET as part of the testing used in establishing whether a patient has cancer.
    Typical purposeEstablish presence of disease when cancer is suspected based on clinical findings.
    Coverage checkDetermine whether PET will influence diagnostic management decisions before authorizing.
    Staging — definition
    DefinitionStaging: use of PET to determine the stage (extent) of the cancer at diagnosis before any treatment is given (initial staging).
    Typical purposeAssess whether cancer is localized vs. metastatic to guide initial treatment planning.
    Common timingPerformed prior to definitive therapy as part of pretreatment workup when indicated by policy/guidelines.
    Restaging — definition
    DefinitionRestaging: imaging after treatment performed when disease recurrence is suspected or to determine extent after completion of a full course of treatment.
    IndicationsUsed for evaluation of suspected recurrence based on signs/symptoms or to document extent following treatment completion.
    Authorization noteRequests for restaging should document clinical suspicion or post-treatment rationale to support medical necessity.
    Surveillance — definition
    DefinitionSurveillance: imaging of asymptomatic patients completed 6 months or more after completion of treatment to detect recurrence (≥12 months for lymphoma).
    Distinguishing featureSurveillance applies to asymptomatic patients without objective signs or symptoms of recurrence.
    Authorization implicationVerify interval since treatment when evaluating requests labeled as surveillance.
    Clinical validity — definition
    DefinitionClinical validity: ability of the PET-based test to detect presence or absence of disease or treatment response, commonly measured by sensitivity, specificity, PPV, and NPV.
    MeasurementAssessed by comparing PET/PET-CT results with conventional imaging, pathology, or clinical follow-up.
    Role in evidence chainClinical validity is necessary groundwork for inferring clinical utility; insufficient validity evidence limits conclusions about utility.
    Clinical utility — definition
    DefinitionClinical utility: whether test results inform management decisions that lead to improved net health outcomes (eg, better survival, avoidance of unnecessary therapy, improved quality of life).
    Evidence requirementStudies should demonstrate how PET/PET-CT results changed treatment and patient outcomes to establish clinical utility.
    Relation to validityClinical utility depends on clinical validity; indirect evidence of utility may be acceptable when validity is strong and change-in-management links to outcomes are plausible.
    FDG-PET / FDG-PET/CT — modalities
    ModalitiesFDG-PET: fluorodeoxyglucose positron emission tomography, using 18F-FDG as tracer, for imaging metabolic activity of tumors.
    Combined modalityFDG-PET/CT: PET performed with concurrently acquired or fused CT to provide metabolic and anatomic correlation.
    Use casesBoth PET alone and PET/CT are discussed in the policy; PET/CT is generally preferred for staging and response assessment per guideline summaries.
    Table 3 — National FDG PET Coverage (definition)
    DefinitionTable 3: National FDG PET Coverage — tabular summary of FDG-PET coverage stance by tumor type and treatment strategy (eg, initial vs subsequent).
    PurposeProvides national coverage designations (Cover, Non-cover, Cover with exceptions) across oncologic conditions to inform policy alignment.
    ExamplesIncludes entries for colorectal, esophagus, pancreas, prostate (initial Non-cover), lymphoma, and other tumor types as shown in the national table.

    Background and Evidence Overview

    Positron emission tomography (PET) is a nuclear imaging modality that uses positron-emitting radiotracers—most commonly 18F-FDG—to image tissue metabolic activity. Tracer selection depends on tumor type and clinical question. The policy notes PET and PET/CT can detect metabolically active disease not seen on conventional imaging and that evidence reviews evaluate whether PET is technically reliable, clinically valid, and clinically useful for specific oncologic purposes. Literature surveillance for this review was updated through September 17, 2025.

    References, Supplemental Tables, and Evidence Appendix

    Table 3 in the policy compiles national FDG PET coverage by tumor type and treatment strategy and is supported by the supplemental references. The table lists coverage status for multiple cancers (for example, colorectal, esophagus, and pancreas are shown as "Cover" for initial and subsequent strategies) and the supplemental material and references provide the source list used to construct the national coverage summary.

    Administrative notes in the policy indicate this gastrointestinal and pancreatic oncologic guidance was split into a separate document; coding and policy language are referenced for prior authorization and claims processing. The coding section clarifies that codes included are informational and that prior authorization requirements depend on the policy criteria and the member's contract.

    The evidence surveillance and literature update section reports the review was informed by systematic reviews, meta-analyses, and primary studies and that the most recent literature update was performed through September 17, 2025. This date should be used as the reference point for the currency of the evidence cited in the policy.

    The policy includes a supplemental references section listing systematic reviews, meta-analyses, guidelines, and trials (see referenced items such as Mahmud et al, Yu et al, Sobhani et al, and ACR/NCCN guidance). These references are provided to substantiate diagnostic accuracy estimates, guideline-based recommendations, and the randomized trial and observational studies referenced throughout the policy.

    Revision History and Document Dates

    2026-01-13policy_reviewLatest

    Last formal policy review completed; document status marked CURRENT and review dates set to 2026-01-13.

    2025-09-17literature_surveillance

    Most recent literature surveillance / evidence update performed through September 17, 2025.

    2025-01-28administrative_posting

    Policy content for Oncologic Applications — Gastrointestinal and Pancreatic was posted (referenced posting date).